Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer's Disease

(marketscreener.com) Outside Biostatisticians with Specific Expertise in Alzheimer’s Disease Will Conduct an Independent Statistical Analysis on The Clinical Dataset. Clinical Dataset May Be Announced Approximately Year-End 2022, Pending Completion of Study Report by Outside Biostatisticians. AUSTIN, Texas, Dec. 06, 2022 -- Cassava Sciences, Inc. , a...https://www.marketscreener.com/quote/stock/CASSAVA-SCIENCES-INC-56537199/news/Cassava-Sciences-Announces-Completion-of-Dosing-in-Open-label-Study-of-Simufilam-for-Alzheimer-s-Dis-42486239/?utm_medium=RSS&utm_content=20221206